Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)

Madhvi Rajpurkar,1 Stacy E Croteau,2 Lisa Boggio,3 David L Cooper4 1Carman and Ann Adams Department of Pediatrics, Children’s Hospital of Michigan/Wayne State University, Detroit, MI, USA; 2Department of Pediatrics, Boston Children’s Hospital/Harvard Medical School, Boston, MA, U...

Full description

Bibliographic Details
Main Authors: Rajpurkar M, Croteau SE, Boggio L, Cooper DL
Format: Article
Language:English
Published: Dove Medical Press 2019-09-01
Series:Journal of Blood Medicine
Subjects:
postmarketing surveillance
acquired hemophilia
congenital hemophilia with inhibitors
congenital factor VII deficiency
Glanzmann’s thrombasthenia
Online Access:https://www.dovepress.com/thrombotic-events-with-recombinant-activated-factor-vii-rfviia-in-appr-peer-reviewed-article-JBM

Internet

https://www.dovepress.com/thrombotic-events-with-recombinant-activated-factor-vii-rfviia-in-appr-peer-reviewed-article-JBM

Similar Items